Merck has gained FDA approval for Enflonsia (clesrovimab), a monoclonal antibody for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants. This entry intensifies competition with established products like Sanofi and AstraZeneca's Beyfortus. The approval arrives amidst turmoil, as the CDC's Advisory Committee on Immunization Practices was abruptly disbanded, casting uncertainty on forthcoming vaccine recommendations. The scheduled June meeting will proceed, but delayed acclimation of new members could affect timely policy guidance, impacting vaccine deployment strategies.